Pooja M Dhupkar

Learn More
Primary and acquired resistance to anticancer antibody immunotherapies presents significant clinical challenges. Here, we demonstrate that proteolytic inactivation of cancer-targeting antibodies is an unappreciated contributor to cancer immune evasion, and the finding presents novel opportunities for therapeutic intervention. A single peptide bond cleavage(More)
Osteosarcoma (OS) is a primary bone malignancy, commonly culminating into aggressive pulmonary metastasis. Despite chemotherapy advances, the 5-year survival of pulmonary metastatic OS remains 25-30%. Immunother-apy is one of the promising novel approaches to target minimal residual and relapsed disease. Previously, we have demonstrated that Liposomal(More)
  • 1